Evidence map›Paper›PMID 40935869›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

The benefit and effectiveness of biodegradable drug-coated stents in treating refractory pediatric laryngotracheal stenosis.

Zhibo Xie, Jiarui Chen, Yangyang Zheng, Xiaoyan Li

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhibo XieDepartment of Otorhinolaryngology Head and Neck Surgery, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, 355 Luding Road, Shanghai, 200062, China.
Jiarui ChenDepartment of Otorhinolaryngology Head and Neck Surgery, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, 355 Luding Road, Shanghai, 200062, China.
Yangyang ZhengDepartment of Otorhinolaryngology Head and Neck Surgery, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, 355 Luding Road, Shanghai, 200062, China.
Xiaoyan LiDepartment of Otorhinolaryngology Head and Neck Surgery, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, 355 Luding Road, Shanghai, 200062, China. lxyshchildren@163.com.ORCID http://orcid.org/0000-0002-5067-4375

Funding

Fundamental Research Funds for the Central Universities No. YG2023ZD23National Natural Science Foundation of China No. 82271151Project of Shanghai Shenkang Hospital Development Center SHDC12023104Shanghai ChenGuang Program No. 21CGA14
6 · The paper itself

Abstract

objectivesLaryngotracheal stenosis (LTS) is one of the most common causes of pediatric airway obstruction. Patients with LTS who receive multiple treatments but still fail to achieve decannulation are defined as having refractory LTS. Treatments for these patients are especially complicated and unsatisfactory. Biodegradable drug-coated stents (BDCSs) have the advantages of providing stable airway support, not requiring a second operation for removal, and preventing restenosis via the slow-release of a coated drug. We aimed to explore the role of BDCSs in treating refractory LTS.

methodThis study enrolled patients with refractory LTS who had undergone previous unsuccessful treatments between 2017 and 2023. Patients were divided into two groups on the basis of whether they received BDCS treatment (BDCS group, n = 30; non-BDCS group, n = 59). Success was defined as achieving decannulation.

resultsAmong the 89 patients with refractory LTS, 66 patients (74.1%) eventually achieved decannulation. The decannulation rate was significantly greater in the BDCS group (P = 0.020). In patients who achieved decannulation, BDCSs significantly reduced the overall duration (P = 0.044) and total number of interventions (P = 0.029). We observed that 12 patients showed improvement in stenosis within one month after the postoperative follow-up, and those with a BDCS had a greater improvement rate (P = 0.047).

conclusionBDCSs could be a promising option for patients with severe refractory LTS.

Indexed as

Absorbable ImplantsDrug-Eluting StentsLaryngostenosisTracheal StenosisAdolescentChildChild, PreschoolFemaleHumansInfantMaleRetrospective StudiesTreatment OutcomeBiodegradable drug-coated stentsEndoscopic techniquesLaryngotracheal reconstructionPediatric patientsRefractory laryngotracheal stenosis

Identifiers

PMID40935869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.